semaglutide acute kidney injury from SGLT2 inhibitors: potential mechanisms In the FLOW trial, researchers

51,56 Zhu et al

The review findings for how GLP-1s affect substance abuse disorders were largely promising, but the authors note that human studies are mostly in the early stages

Therefore, l-ARG supplementation might be considered an attractive approach to ED management in specific settings, such as mildmoderate vasculogenic ED, with an additional potential preventive value for future CVD

It was not as potent as the high-dose once-daily liraglutide (well see below) but it was a solid improvement over adding a placebo

A "start low and go slow" strategy helps to mitigate these issues and improve long-term outcomes